Evolent Health

EVH

Market cap $280M

WASHINGTON, April 7, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its first quarter 2026 financial results on Thursday, May 7, 2026, before market open, with a conference call to follow at 8 a.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.

Industry veteran brings track record of innovation from GHX, Change Healthcare, UnitedHealth Group and Amazon. WASHINGTON, March 19, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced the appointment of health care technology leader and AI innovator Archie Mayani as chief product officer (CPO).

WASHINGTON, Feb. 26, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that members of its executive management team will participate in upcoming investor conferences.  A live audio-only webcast and replay for these events will be available on the "Events and Presentations" section of Evolent's investor relations website.

Evolent Health, Inc. is rated a Buy, with turnaround momentum and risk/reward now favoring upside after recent operational and strategic shifts. EVH's Performance Suite model now covers ~90% of revenue, offering risk protection and greater earnings predictability, despite near-term profit headwinds from new contract launches. Oncology drives EVH's growth, with strong customer retention (>98%) and cost discipline via AI automation and workforce efficiencies delivering $20M+ in annualized savings.

Evolent Health, Inc. (EVH) Q4 2025 Earnings Call Transcript

While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Evolent Health (EVH) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $0.02 per share a year ago.

WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended December 31, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "In 2025 we executed on our earnings targets, continued to grow market share, renewed customers at strong rates, and continued the migration of Performance Suite clients to our enhanced Performance Suite contract model.

WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its 2025 fourth quarter and year-end financial results on Tuesday, February 24, 2026, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.

WASHINGTON, Jan. 2, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, announced that the Compensation Committee of Evolent's Board of Directors approved the grant of a one-time time-based restricted stock unit award covering 587,500 shares of Evolent Class A common stock, par value $0.01 per share (the "Inducement Award"), to Mr. Mario Ramos ("Mr.